X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboratin aims to evaluate the investigational cereblon E3 ligase modulator agent mezigdomide in combination with Karyopharm's selinexor, an approved first-in-class inhibitor of XPO1, plus dexamethasone in patients with relapsed/refractory multiple myeloma.
Lead Product(s): Mezigdomide,Selinexor
Therapeutic Area: Oncology Product Name: BMS-986348
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Bristol Myers Squibb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 30, 2023
Details:
Xpovio (selinexor) is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of selective Inhibitor of Nuclear Export (SINE) compounds which down-regulates the levels of multiple oncogenic proteins, being developed for the treatment of cancer.
Lead Product(s): Selinexor,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
Xpovio (selinexor) is a first-in-class, oral exportin 1 (XPO1) inhibitor and currently investigated in combination with ruxolitinib in JAKi-naïve patients with myelofibrosis.
Lead Product(s): Selinexor,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Details:
Nexpovio (selinexor) reversibly inhibits nuclear export of tumor suppressor proteins (TSPs), growth regulators, and mRNAs of oncogenic proteins by blocking exportin 1 (XPO1).
Lead Product(s): Selinexor,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: Nexpovio
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Menarini
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
Xpovio (selinexor) is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds to be approved for the treatment of cancer.
Lead Product(s): Selinexor
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Foundation Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 10, 2023
Details:
XPOVIO (selinexor) is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds to be approved for the treatment of cancer.
Lead Product(s): Selinexor,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
NEXPOVIO (Selinexor) is a first-in-class, oral exportin 1 (XPO1) inhibitor, functions by selectively binding to and inhibiting the nuclear export protein exportin 1 (XPO1, also called CRM1).
Lead Product(s): Selinexor,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: Nexpovio
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Menarini
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022
Details:
Eltanexor (KPT-8602/ATG-016) is an investigational novel SINE compound that functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus.
Lead Product(s): Eltanexor
Therapeutic Area: Oncology Product Name: ATG-016
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2022
Details:
Encouraging initial data observed in phase 1/2 study of Nexpovio (selinexor) in combination with ruxolitinib in treatment-myelofibrosis, favorable tolerability with nodose-limitingg toxicities and 75% of evaluable patients demonstrating ≥35% spleen volume reduction at week 12.
Lead Product(s): Selinexor,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: Nexpovio
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
XPOVIO (selinexor) is a first-in-class, oral exportin 1 (XPO1) inhibitor and the first of Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds to be approved for the treatment of cancer.
Lead Product(s): Selinexor,Dexamethasone,Pomalidomide
Therapeutic Area: Oncology Product Name: Xpovio
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: European Myeloma Network
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
